search panel

Current News

  • The Fundraising Complex

    The Fundraising Complex

    “It was almost like you have to say, ‘By the way, it wasn’t his fault that he got this disease.’” - Maria Amaral

    Lung is the deadliest cancer, accounting for one-quarter of cancer deaths by killing 20,000 Canadians each year — more than breast, colorectal and prostate cancers combined. But it doesn’t get a run for a cure or a dedicated day when professional athletes wear dedicated colours to raise awareness.

    Yet when it comes to Canadian research funding the numbers are flipped. Lung cancer receives about six per cent, while breast cancer gets more than a quarter of dollars raised.

    Read More

  • Volunteer Week

    Volunteer Week

    Lung Cancer Canada is celebrating Volunteer Week by thanking Canada’s 12.7 million #volunteers! We've had the pleasure of working with many GREAT volunteers who give up their time to help support lung cancer patients, their families and promote lung cancer awareness.  For that we say THANK YOU!!

    Read More

  • Geoffrey Ogram Memorial Research Fund

    Geoffrey Ogram Memorial Research Fund

    The Geoffrey Ogram Memorial Research Fund has been established to foster innovative research in lung cancer.

    Being a never-smoker, Geoffrey Ogram was shocked to receive a diagnosis of lung cancer in 2010. Despite two years of non-progression, successful surgery and targeted therapy, Geoffrey passed away on Friday April 15th, 2016. Geoffrey was a tireless activist for lung cancer awareness and research.

    $54,415.00 raised to date
    Goal: $100,000

    Read More

  • INESSS in Quebec Approves Opdivo as Exceptional Drug Status

    INESSS in Quebec Approves Opdivo as Exceptional Drug Status

    Immunotherapy Opdivo (nivolumab) has been approved with Exceptional Drug Status in Quebec for the treatment of NSCLC!

    Read More

  • Lung Cancer Connection - Winter 2017

    Lung Cancer Connection - Winter 2017

    Winter may be officially over (finally!) but check out LCC's Lung Cancer Connection Winter 2017 Newsletter!

    Read More

  • pERC Issues Positive FINAL Recommendation for Zykadia

    pERC Issues Positive FINAL Recommendation for Zykadia

    Today, the pCODR Expert Review Committee (pERC) issued the Final Recommendation for ceritinib (Zykadia) resubmission for NSCLC.  pERC recommends reimbursement of ceritinib (Zykadia) monotherapy for patients with ALK positive locally NSCLC.

    This is more great news for lung cancer patients!  Lung Cancer Canada encourages the pan-Canadian Pricing Alliance (pCPA) to begin negotiations as soon as possible so that patients are not left waiting for much needed therapy.

    Read More

Latest Tweets